Abstract
The authors wish to make corrections to their article:
Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research. Drugs in Context 2019; 8: 212605. DOI: 10.7573/dic.212605
Corrigendum
The authors regret that there are errors in their original paper.
1. The following shows where original text has been removed (strikethrough) and new wording introduced (underlined).
Page 3, section on Berinert®
In 2009, the US FDA approved Berinert® (CSL Behring), a pasteurized plasma-derived C1-INH concentrate, available for intravenous (IV) administration in patients needing on-demand therapy. This drug was also not approved for short-term prophylaxis in the EU in 2013. but is used off-label for this purpose.
The following reference from the Head of Medicine website (EU approval document) should also be added to this statement: https://mri.cts-mrp.eu/Human/Downloads/DE_H_0481_003_PAR.pdf
Page 5, section on Haegarda®
C1-INH (SC) Haegarda®
Haegarda® and Berinert® 2000/3000 (CSL Behring) were approved (US and EU) was approved by the FDA in 2017 as the first subcutaneous C1 inhibitor concentrate, also indicated for self-administration, at the dose of 60 IU/kg twice weekly. Nevertheless, the European Medicines Agency did not formally approve the marketing of the drug.29
-
2. Table 1 lists two products Berinert® and Haegarda® on separate lines; however, they should be grouped together as follows:
Drug name Active substance Type and action Administration Indication T1/2 Berinert®, CSL Behring C1-INH Plasma-derived C1-INH concentrate pasteurized, nanofiltered IV On-demand, short-term prophylaxis 36–48 hours Berinert® 2000/3000 (Haegarda® brand name in the United States and Canada) C1-INH Plasma-derived C1-INH concentrate pasteurized, nanofiltered SC Long-term prophylaxis 69 hours